Follow the EMPULSE: In-Hospital Initiation of Empagliflozin for Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction
European Journal of Heart Failure · 2024
DOI: 10.1002/ejhf.3256 ↗Kurz gefasst
Editorial in der Zeitschrift European Journal of Heart Failure, 2024. Verfasst von Tann Lien und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA. Hauptthemen laut MEDLINE: Heart Failure, Glucosides, Benzhydryl Compounds, Stroke Volume. Die Arbeit nennt 16 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
This article refers to 'Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction -Results from the EMPULSE trial' by J. Tromp et al., published in this issue on pages 963-970.Heart failure (HF) is a global pandemic expected to affect over 64 million people worldwide.1 In the United States, HF accounts for more than 1 million hospitalizations with costs exceeding $40 billion. 1 Researchers and clinicians continue to investigate innovative and effective ways of treating HF.Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as a first-line treatment option for HF.Prior studies have evaluated the benefits of initiating SGLT2 inhibitors in stable ambulatory settings.2,3 SOLOIST-WHF was the first trial to extrapolate efficacy of sodium-glucose cotransporter inhibition across left ventricular ejection fraction (LVEF) categories but was not exclusive to the acute setting.4 The landmark EMPULSE trial investigated the efficacy of early initiation of SGLT2 inhibitors specifically in hospitalized patients showing statistical and clinical significance in improving clinical and patient-centred outcomes.5 In this issue of the Journal, Tromp et al. 6 conducted a post-hoc analysis of the EMPULSE trial and explored the efficacy, safety, and tolerability of empagliflozin across the full range of LVEF.EMPULSE enrolled 530 patients hospitalized for HF with symptoms regardless of LVEF.These patients were randomized in a double-blind, 1:1 ratio to receive empagliflozin 10 mg daily or a matching placebo.Of note, participants were initiated on therapy between 24 h and 5 days following admission and stabilization.Stabilization was defined as systolic blood pressure ≥100 mmHg with no symptoms of hypotension, no increase in intravenous diuretics or use of intravenous vasodilators within 6 h of randomization, and/or no use of inotropic therapies within 24 h of randomization.Benefits of empagliflozin initiated in the hospital setting, withThe opinions expressed in this article are not necessarily those of the Editors of the European Journal of Heart Failure or of the European Society of Cardiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA.
- Department of Cardiology, Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA.
- Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Zitieren
APA
Lien, T., Srikanth, K., & Ambrosy, A. P. (2024). Follow the EMPULSE: In-Hospital Initiation of Empagliflozin for Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3256
Vancouver
Lien T, Srikanth K, Ambrosy AP. Follow the EMPULSE: In-Hospital Initiation of Empagliflozin for Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction. European Journal of Heart Failure. 2024. doi:10.1002/ejhf.3256
BibTeX
@article{Lien2024,
author = {Lien, Tann and Srikanth, Kishan and Ambrosy, Andrew P},
title = {Follow the EMPULSE: In-Hospital Initiation of Empagliflozin for Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction},
journal = {European Journal of Heart Failure},
year = {2024},
doi = {10.1002/ejhf.3256}
}
EUVIMED